Literature DB >> 29211320

Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.

Darren Ming-Chun Poon1, Chi-Kwok Chan2, Tim-Wai Chan3, Foon-Yiu Cheung4, Philip Wai-Kay Kwong5, Eric Ka-Chai Lee6, Angus Kwong-Chuen Leung7, Simon Yiu-Lam Leung8, Wai-Kit Ma9, Hing-Shing So10, Po-Chor Tam9, Lap-Yin Ho11.   

Abstract

To establish a set of consensus statements to facilitate physician management strategies for patients with metastatic prostate cancer (mPCa) in Hong Kong. A local expert consensus was organized jointly by the two main professional organizations representing prostate cancer specialists in Hong Kong. A total of 12 experts were included in the consensus panel. Six of the most crucial and relevant areas of debate regarding the management of mPCa were identified. With the use of a modified Delphi method, several panel meetings were held for the members to discuss their clinical experience and the published literature relevant to the areas of debate. At the final meeting, each drafted statement was voted on by every member based on its practicability of recommendation in the locality. After the panel voting, a total of 45 consensus statements regarding the management of mPCa were ultimately accepted and established. The consensus statements were primarily derived from the latest clinical evidence and major overseas guidelines, with the consideration of local clinical experience and practicability. These are considered applicable recommendations for Hong Kong physicians for the management of mPCa patients.
© 2017 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International.

Entities:  

Keywords:  #PCSM; #ProstateCancer; castration-naïve prostate cancer; castration-resistant prostate cancer; consensus; metastatic prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29211320     DOI: 10.1111/bju.14091

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  3 in total

1.  Volumetric-Modulated Arc Radiotherapy with Daily Image-Guidance Carries Better Toxicity Profile for Higher Risk Prostate Cancer.

Authors:  Ahmad I Ghanem; Amr A Elsaid; Mohamed A Elshaikh; Gehan A Khedr
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

Review 2.  Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.

Authors:  Wai-Kit Ma; Darren Ming-Chun Poon; Chi-Kwok Chan; Tim-Wai Chan; Foon-Yiu Cheung; Lap-Yin Ho; Eric Ka-Chai Lee; Angus Kwong-Chuen Leung; Simon Yiu-Lam Leung; Hing-Shing So; Po-Chor Tam; Philip Wai-Kay Kwong
Journal:  BJU Int       Date:  2019-02-05       Impact factor: 5.588

Review 3.  Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer.

Authors:  Darren M C Poon; Kuen Chan; Tim Chan; Foo-Yiu Cheung; Daisy Lam; Martin Lam; Ka-Suet Law; Conrad Lee; Eric K C Lee; Angus Leung; Henry Sze; Chi-Chung Tong; Kenneth C W Wong; Philip Kwong
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.